The effect of cigarette modified risk claims and brand on perceived risk, product appeal, and use intentions

• Erin Keely O’Brien ,

  Roles Conceptualization, Writing – original draft, Writing – review & editing

  * E-mail: erin.obrien@fda.hhs.gov, erinkeelyobrien@gmail.com

  Affiliation Office of Science, Center for Tobacco Products, Food and Drug Administration (FDA), Silver Spring, MD, United States of America

  https://orcid.org/0000-0002-6208-329X

  ⨯
• Andrea L. Ruybal,

  Roles Formal analysis, Writing – review & editing

  Affiliation Office of Science, Center for Tobacco Products, Food and Drug Administration (FDA), Silver Spring, MD, United States of America

  https://orcid.org/0000-0003-2610-090X

  ⨯
• Amber R. . Koblitz,

  Roles Conceptualization, Methodology, Project administration, Writing – original draft, Writing – review & editing

  Affiliation Office of Science, Center for Tobacco Products, Food and Drug Administration (FDA), Silver Spring, MD, United States of America

  ⨯
• Sarah E. Johnson

  Roles Conceptualization, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing

  Affiliation Office of Science, Center for Tobacco Products, Food and Drug Administration (FDA), Silver Spring, MD, United States of America

  ⨯